A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria

To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.

开始日期2023-01-25

申办/合作机构

Curacle Co., Ltd.

KCT0004233 / Completed临床2期

A multi-center, randomized, double-blinded, placebo-controlled, parallel Phase ?a clinical trial for the efficacy assessment and safety evaluation by treating CU01-1001 for 12 weeks in type 2 diabetic nephropathy patients with albuminuria.

开始日期2019-09-02

申办/合作机构

Curacle Co., Ltd.

100 项与 CU-01 相关的临床结果

登录后查看更多信息

100 项与 CU-01 相关的转化医学

登录后查看更多信息

100 项与 CU-01 相关的专利（医药）

登录后查看更多信息

项与 CU-01 相关的文献（医药）

2024-12-01·Bioorganic Chemistry

Copper(II) aromatic heterocyclic complexes of Gatifloxacin with multi-targeting capabilities for antibacterial therapy and combating antibiotic resistance

Article

作者: Li, Jin-Hao ; He, Liang ; Chen, Bai-Hua ; Pan, Zheng-Yin ; Liu, Qi-Yan ; Liu, Ya-Shu ; Wu, Xiao-Yin ; Jiang, Shan ; Dong, Jia-Hao ; Liu, Yingju

In recent years, the pace of novel antibiotic development has been relatively slow, intensifying the urgency of the antibiotic resistance issue. Consequently, scientists have turned their attention to enhancing antibiotic activity by coordinating antibiotics with metal elements. This study designs and synthesizes three novel antibacterial copper complexes based on Gatifloxacin. These complexes exhibit potent antibacterial activity, notably Cu-1, with a minimum inhibitory concentration (MIC) of only 0.063 μg/mL against Staphylococcus aureus (S.aureus), demonstrating potent bacteriostatic capabilities. Further investigations unveil the antibacterial mechanisms of complex Cu-1, revealing its ability not only to suppress the activities of DNA gyrase and topoisomerases IV, but also to effectively inhibit biofilm formation and disrupt the integrity of cell membrane. This multi-targeting action contributes to mitigating the risk of bacterial resistance emergence. Additionally, synergy between Cu-1 and conventional antibiotics is confirmed through checkerboard assays, offering novel strategies for antibacterial therapy. In vivo experiments using a murine model of S.aureus infection demonstrate the significant antibacterial efficacy of Cu-1, providing robust support for its potential in treating S.aureus infections. This study demonstrates that the coordination complexes formed by copper, Gatifloxacin and suitable aromatic heterocyclic ligands exhibit multi-targeting characteristics against bacteria, offering a new direction for combating antibiotic resistance in antibacterial therapy.

2020-01-29·Metallomics2区 · 生物学

Anti-cancer activities of metal-based complexes by regulating the VEGF/VEGFR2 signaling pathway and apoptosis-related factors Bcl-2, Bax, and caspase-9 to inhibit angiogenesis and induce apoptosis

2区 · 生物学

Article

作者: Zhang, Pei-Lu ; Luo, Zhao-Hui ; Wang, Ya-Nan ; Liu, Mei-Rong ; Li-Fang, Huang ; Liu, Han-Fu ; Qin, Xiu-Ying

AbstractThree novel single crystals of the metal-based complexes Cu-1, Cu-2, and Co-1 were obtained and characterized. Compared with Cu-2 and Co-1, Cu-1 showed remarkable activities of anti-cervical cancer, anti-cisplatin-resistant non-small cell lung cancer and anti-angiogenesis by downregulating the expressions of important proteins in the VEGF/VEGFR2 signaling pathway to inhibit angiogenesis and cancer cell proliferation, induce apoptosis, and suppress migration and metastasis. Moreover, Cu-1 dramatically inhibited the expression of the anti-apoptotic protein Bcl-2 and up-regulated the expressions of the proapoptotic proteins caspase-9 and Bax to induce the apoptosis of tumor cells, simultaneously decreasing the density of endothelial cells to inhibit tumor angiogenesis in cisplatin-resistant tumors.

100 项与 CU-01 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白蛋白尿	临床2期	韩国	Curacle Co., Ltd.	2023-01-25
非胰岛素依赖型糖尿病2	临床2期	韩国	Curacle Co., Ltd.	2023-01-25
2型糖尿病肾脏病	临床2期	韩国	Curacle Co., Ltd.	2023-01-25